Nov� trendy v p��stupu k l��b� diabetu 2. typu - post�ehy a benefity v ambulantn� praxi diabetologa (original) (raw)

Klin Farmakol Farm. 2021;35(4):118-123 | DOI: 10.36290/far.2021.027

1Klinika intern�, geriatrie a praktick�ho l�ka�stv� LF MU a FN, Brno

2DIASTOP, diabetologick� a intern� ambulance, Brno

�vod: Diabetes mellitus 2. typu (DM2T) p�edstavuje zv��en� riziko rozvoje mikro- i makroangiopatick�ch komplikac�. Nov� antidiabetika maj� vy��� ��innost i bezpe�nost, m�n� ne��douc�ch ��ink� a �adu protektivn�ch charakteristik u�it� v mnoha sm�rech.

Kl��ov� slova: diabetes mellitus 2. typu, gliptiny, glifloziny, inkretinov� mimetika, trendy zm�n v p��stupu k terapii.

New trends in the approach to the treatment of type 2 diabetes - observations and benefits in the outpatient practice of a diabetologist

Introduction: Type 2 diabetes mellitus (DM2T) constitutes an increased risk of developing micro- and macroangiopathic complications. New antidiabetics have higher efficacy and safety, fewer side effects and a number of protective characteristics of use in many ways.

Patients and methods: In the years 2011-2021, about 2000 DM2Ts were permanently treated in our diabetological surgery. In 2021 it was a total of 2,562 of all registered diabetics. Of this number, there were 2,398 cases of T2DM (1,203 men and 1,195 women). A total of 2110 type 2 diabetics (88%) of a mean age of 69.7 ± 11.6 years were treated with antidiabetic drugs, incretin mimetics or insulin in 2021. In the cohort, we analyzed regarding the use of new antidiabetics (NAD): age, diabetes duration, obesity, comorbidities, number of drugs used and diabetic complications, in particular to evaluate the increase in NAD use between 2011-2021.

Results: In 2021 in our diabetological outpatient clinic of patients with DM2T we used: diabetic diet only 12%; oral antidiabetics (PAD) 53%; monotherapy with insulin or insulin analogues 17% and a combination of insulin and PAD (18%). NAD (gliptins, gliflozins and incretin mimetics) were used either within monotherapy or in combination in patients with DM2T in 2021 in a total of 35%. Our retrospective data analysis showed a steady trend in increasing the use of NAD (most gliptins) both as monotherapy and in combination with metformin. Thanks to new treatment options, we have also seen a significant improvement in the compensation of type 2 diabetics.

Conclusion: Our communication points to a massive shift and change in approach to DM2T therapy in the last decade in routine. outpatient practice in the use of NAD, which is undoubtedly related to their benefits for the cardiovascular and renal systems.

Zve�ejn�no: 4. leden 2022 Zobrazit citaci

St�hnout citaci

Reference

  1. Pelik�nov� T, Barto� V, eds. Praktick� diabetologie. Praha, Maxdorf, 2018:814.
  2. Haluz�k M a kol. Praktick� l��ba diabetu. Praha, Mlad� fronta, 2013:368.
  3. Nasykhova YA, Tonyan ZN, Mikhailova A, Danilova MM, Glotov AS. Pharmacogenetics of Type 2 Diabetes-Progress and Prospects. Int J Mol Sci 2020;21(18):6842. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  4. American Diabetes Association. Standards of Medical Care in Diabetes - 2013. Diabetes Care 2013;36(Suppl.1):S11-S66. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  5. Sinclair AJ, Paolisso G, Castro M, et al. European Diabetes Working Party for Older People. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab 2011;37(Suppl. 3):S27-S38. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  6. Yandrapalli S, Malik A, Horblitt A, et al. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2. Cardiol Rev 2020;28(5):219-235. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  7. Sachinidis A, Nikolic D, Stoian AP, et al. Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism 2020;111:154343. Epub 2020 Aug 16. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  8. Pinto LC, Rados DV, Remonti LR, et al. Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis. J Clin Endocrinol Metab 2020;105(11):dgaa534. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  9. Fillit HM, Rockwood K, Young JB. Brocklehurst's Textbook of Geriatric Medicine and Gerontology. Seventh ed. Philadelphia, Elsevier Health Sciences, 2016:1119.
  10. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44(Suppl. 1):S111-S124. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  11. Bhatt AS, Luo N, Solomon N, et al. TECOS Study Group. International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. Am Heart J 2019;218:57-65. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  12. Singh AK, Singh R. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs. Expert Rev Clin Pharmacol 2017;10(4):429-442. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  13. Mohammedi K, Woodward M, Hirakawa Y, et al. ADVANCE Collaborative Group. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovasc Diabetol 2016;15(1):129. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  14. And�l M, N�mcov� V, Pavl�kov� N, et al. Faktory vedouc� k po�kozen� a destrukci B-bun�k Langerhansov�ch ostr�vk� pankreatu. Vnit� L�k 2014;60(9):684-690. P�ej�t na PubMed...
  15. Charytan DM, Solomon SD, Ivanovich P, et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2019;21(5):1199-1208. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  16. Fayfman M, Galindo RJ, Rubin DJ, et al. A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes. Diabetes Care 2019;42(3):450-456. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  17. Mo D, Liu S, Ma H, et al. Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study. Drug Des Devel Ther 2019;13:2769-2776. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  18. Frias JP, Zimmer Z, Lam RLH, et al. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. Diabetes Obes Metab 2019;21(5):1128-1135. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  19. M�ller-Wieland D, Kellerer M, Cypryk K, et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab 2018;20(11):2598-2607. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  20. Matthews DR, Paldanius PM, Proot P, et al. Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes. Diabet Med 2019;36(4):505-513. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  21. Jia S, Wang Z, Ruobing Han 1, et al. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis. Acta Diabetol 2021;58(1):5-18. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  22. Negro R, Greco EL, Greco G. Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients. Exp Clin Endocrinol Diabetes 2019;127(4):215-219. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  23. Gutierrez JA, Scirica BM, Bonaca MP, et al. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in atients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). Am J Cardiol 2019;123(1):145-152. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  24. Mosenzon O, Leibowitz G, Bhatt DL et al. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care 2017;40(1):69-76. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  25. Zannad F, Cannon CP, Cushman WC, et al. EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial Lancet. 2015;385(9982):2067-2076. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  26. Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®). Diab Vasc Dis Res 2015;12(3):164-174. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  27. Rosenstock J, Perkovic V, Johansen OE. CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2019;321(1):69-79. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  28. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16(11):642-653. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  29. Chun-Xing Li, Shuo Liang, Lingyan Gao, Hua Liu. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis. PLoS One. 2021;16(2):e0244689. eCollection 2021. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  30. Leite KM, Long AM, Ostroff ML, Borges L, Braden G. A Review of the Renoprotective Effects of Novel Antidiabetic Agents. J Pharm Pract 2021;34(1):141-148. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  31. Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation 2019;139(11):1384-1395. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  32. Mahaffey KW, Neal B, Perkovic V, et al. CANVAS Program Collaborative Group. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018;137(4):323-334. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  33. Wiviott SD, Raz I, Bonaca MP et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J 2018;200:83-89. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  34. Bae JH, Eun-Gee Park, Kim S, Kim SM, Hahn S, Kim NH. Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Endocrinol Metab (Seoul) 2021;36(2):388-400. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  35. Linong Ji, Xiaolin Dong, Yiming Li et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab 2021;23(2):404-414. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  36. Mather KJ, Considine RV, Hamilton L, et al. Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes. J Clin Endocrinol Metab 2018;103(9):3456-3465. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  37. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation 2019;139(17):2022-2031. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  38. Liu X, Huang J, Li J, Mao Q, He J. Effects of Liraglutide Combined with Insulin on Oxidative Stress and Serum MCP-1 and NF-kB Levels in Type 2 Diabetes. J Coll Physicians Surg Pak 2019;29(3):218-221. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  39. Ba J, Han P, Yuan G, et al. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. J Diabetes 2017(7):667-676. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  40. Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era? J Diabetes Complications 2020; 34(12): 107723. Epub 2020 Aug 26. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  41. Yan Yang, Zixin Cai, Jingjing Zhang. DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis. PLoS One. 2021;16(5):e0251916. eCollection 2021. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...
  42. Bassendine MF, Bridge SH, McCaughan GW, Gorrell MD. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity? J Diabetes 2020;12(9):649-658. Epub 2020 May 27. P�ej�t k p�vodn�mu zdroji... P�ej�t na PubMed...